Summary & Overview
HCPCS Q4169: Artacent Wound, Per Square Centimeter
HCPCS Level II code Q4169 designates the use of Artacent wound product billed per square centimeter as an add-on code to be reported in addition to a primary procedure. This code matters nationally because it standardizes reporting for a specific wound care product tied to surface area, supporting accurate claims and product utilization tracking across outpatient and ambulatory care settings. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what the code represents clinically and operationally, which payers commonly cover or process claims for this add-on wound product, and how the code is used alongside primary wound procedures. The summary covers benchmarks for utilization and reimbursement patterns where available, notes common billing practices and allowable billing modifiers, and highlights clinical contexts in which an area-based wound product like Artacent is typically applied. Data not available in the input is explicitly noted where applicable. The publication provides concise operational context for revenue cycle, coding, and clinical staff responsible for documenting and submitting claims involving HCPCS Level II code Q4169.
Billing Code Overview
HCPCS Level II code Q4169 represents Artacent wound, billed per square centimeter. This code is an add-on, list separately in addition to primary procedure and is used to report the application or use of the Artacent wound product based on the treated wound surface area.
Service type: Wound care product application
Typical site of service: Hospital outpatient departments, outpatient wound care clinics, physician offices, and other ambulatory care settings where wound management procedures are performed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic or non-healing cutaneous wound such as a diabetic foot ulcer, venous stasis ulcer, pressure ulcer, or traumatic skin loss that has failed standard conservative therapy. The wound care team (often a wound care physician or advanced practice provider with nursing support) evaluates wound size and depth, performs debridement and cleansing, and determines that an advanced biologic topical graft product, billed with Q4169 per square centimeter as an add-on implantable wound matrix (Artacent wound), is indicated to promote granulation and closure. The clinical workflow includes wound assessment and measurement (documenting square centimeters treated), obtaining informed consent, application of the product in a procedure room or outpatient wound clinic, securement of the graft and appropriate dressing, and scheduling follow-up visits for assessment and additional treatments. Typical sites of service are outpatient wound care clinics, outpatient hospital departments, ambulatory surgical centers, and occasionally inpatient bedside applications for complex patients. Documentation should include wound dimensions, prior treatments, indication for biologic application, exact quantity (cm2) of product used, lot numbers if required, and post-application care instructions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstances apply |